The assessed prognostic and predictive value of AR/ER ratio in patients with primary HR+/HER2- BC treated with Tamoxifen (24) suggested that this marker could be useful for prognostic classification of luminal cancers. This evidence concerns the gene ESR1 and breast cancer.